Trials / Active Not Recruiting
Active Not RecruitingNCT07220954
A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234
A Phase I, Single-Dose, Open-Label, Sequential, Randomised, Crossover Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD6234 in Participants Living With Overweight or Obesity
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of AZD6234. This study will take place at one site in Nottingham, United Kingdom, and will enrol 21 healthy men and women aged 18-55 years.
Detailed description
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of AZD6234. This study will take place at one site in Nottingham, United Kingdom. It plans to enrol 21 healthy men and women aged 18-55 years. Each volunteer will take part in 4 treatment periods and receive different formulations of AZD6234, by injection under the skin into the abdomen (stomach). In each period they'll be given a single dose without food. They'll stay in the clinic for 6 nights on 4 occasions, attend up to 10 outpatient visits, and take up to 19 weeks to finish the study. Blood and urine samples will be collected to: measure the amount of AZD6234 and its breakdown products, do safety tests and assess the effect of the test medicine on the immune system response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD6234 Formulation 1 | AZD6234 Formulation 1 will be administered as a single SC injection |
| DRUG | AZD6234 Formulation 2 (low concentration) | AZD6234 Formulation 2 (low concentration) will be administered as a single SC injection |
| DRUG | AZD6234 Formulation 2 (high concentration) | AZD6234 Formulation 2 (high concentration) will be administered as a single SC injection |
| DRUG | AZD6234 Formulation 3 | AZD6234 Formulation 3 will be administered as a single SC injection |
Timeline
- Start date
- 2025-11-11
- Primary completion
- 2026-03-24
- Completion
- 2026-03-25
- First posted
- 2025-10-24
- Last updated
- 2026-04-03
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT07220954. Inclusion in this directory is not an endorsement.